Related Experiment Video
Updated: Jan 22, 2026
10:03
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
Published on: July 5, 2019
9.3K
Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells
Kimmo Kettunen1, Peter J Boström2, Tarja Lamminen3
1Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland.
European Urology
|July 2, 2019
Summary
Conditionally reprogrammed bladder cancer cells can predict drug sensitivity. This method offers a promising approach for personalizing bladder cancer treatment strategies when standard therapies fail.
Area of Science:
- Oncology
- Cell Biology
- Genomics
Background:
- Cisplatin-based chemotherapy is not effective for all muscle-invasive bladder cancer patients.
- There is a need for methods to predict individual drug sensitivities in bladder cancer.
Purpose of the Study:
- To investigate the utility of conditionally reprogrammed (CR) cells for characterizing bladder cancer (BC) and for personalized drug sensitivity screening.
- To assess the feasibility of using CR cells to identify novel therapeutic agents for bladder cancer.
Main Methods:
- Established CR cell cultures from six bladder cancer tumors.
- Performed genomic, transcriptomic, and protein expression profiling on CR cultures and parental tumors.
- Conducted drug sensitivity screening on representative CR cultures.
Main Results:
- Four CR cultures were successfully propagated and compared to parental tumors.
- Two CR cultures (urothelial carcinoma and small cell neuroendocrine carcinoma [SmCC]) accurately represented their parental tumors.
- Both CR cultures responded to standard chemotherapy agents and other conventional drugs; SmCC cells showed sensitivity to statins.
Conclusions:
- Conditionally reprogrammed cells are a viable platform for personalized drug sensitivity testing in bladder cancer.
- CR cells can aid in developing personalized treatment strategies for bladder cancer patients.
- This approach may help identify novel drugs, including statins for SmCC.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
01:21Drug Dosing: Obese Patients
235
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
01:29Somatic to iPS Cell Reprogramming
2.6K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.6K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
269
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
198
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198